Molecular basis for the mechanism of action of an anti-TACE antibody

mAbs

Volumn 8, Issue 8, 2016, Pages 1598-1605

  Peng, Li ^a   Cook, Kimberly ^a   Xu, Linda ^a   Cheng, Li ^a   Damschroder, Melissa ^a   Gao, Changshou ^a   Wu, Herren ^a   Dall'Acqua, William F ^a  

^a MEDIMMUNE   (United States)

Author keywords

ADAM17; antibody homology modeling; epitope mapping; mutagenesis; protein docking; TACE

Indexed keywords

ANTIBODY; EPITOPE; MEDI 3622 ANTIBODY; RECOMBINANT ENZYME; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG; ADAM17 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANTIBODY SPECIFICITY; ANTIGEN BINDING; BINDING COMPETITION; CATALYSIS; CHEMICAL STRUCTURE; CONTROLLED STUDY; DNA HAIRPIN; DRUG MECHANISM; EPITOPE MAPPING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MOLECULAR INTERACTION; MUTAGENESIS; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SURFACE PLASMON RESONANCE; IMMUNOLOGY; MOLECULAR MODEL;

ADAM17 PROTEIN; ANTIBODIES, MONOCLONAL; EPITOPE MAPPING; HUMANS; MODELS, MOLECULAR;

EID: 84989233344     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1226716     Document Type: Article

References (32)

1. D.R.Edwards, M.M.Handsley, C.J.Pennington. The ADAM metalloproteinases. Mol Aspects Med 2008; 29:258-89; PMID:18762209; http://dx.doi.org/10.1016/j.mam.2008.08.001
2. R.A.Black, C.T.Rauch, C.J.Kozlosky, J.J.Peschon, J.L.Slack, M.F.Wolfson, B.J.Castner, K.L.Stocking, P.Reddy, S.Srinivasan, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385:729-33; PMID:9034190; http://dx.doi.org/10.1038/385729a0
3. M.L.Moss, S.L.Jin, M.E.Milla, D.M.Bickett, W.Burkhart, H.L.Carter, W.J.Chen, W.C.Clay, J.R.Didsbury, D.Hassler, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997; 385:733-6; PMID:9034191; http://dx.doi.org/10.1038/385733a0
4. S.W.Sunnarborg, C.L.Hinkle, M.Stevenson, W.E.Russell, C.S.Raska, J.J.Peschon, B.J.Castner, M.J.Gerhart, R.J.Paxton, R.A.Black, et al. Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol Chem 2002; 277:12838-45; PMID:11823465; http://dx.doi.org/10.1074/jbc.M112050200
5. U.Sahin, G.Weskamp, K.Kelly, H.M.Zhou, S.Higashiyama, J.Peschon, D.Hartmann, P.Saftig, C.P.Blobel. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004; 164:769-79; PMID:14993236; http://dx.doi.org/10.1083/jcb.200307137
6. P.R.Murumkar, R.Giridhar, M.R.Yadav. Novel methods and strategies in the discovery of TACE inhibitors. Exp Opin Drug Discovery 2013; 8:157-81; PMID:23231541; http://dx.doi.org/10.1517/17460441.2013.744745
7. S.DasGupta, P.R.Murumkar, R.Giridhar, M.R.Yadav. Current perspective of TACE inhibitors:a review. Bioorg Med Chem 2009; 17:444-59; PMID:19095454; http://dx.doi.org/10.1016/j.bmc.2008.11.067
8. K.Maskos, C.Fernandez-Catalan, R.Huber, G.P.Bourenkov, H.Bartunik, G.A.Ellestad, P.Reddy, M.F.Wolfson, C.T.Rauch, B.J.Castner, et al. Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme. Proc Natl Acad Sci U S A 1998; 95:3408-12; PMID:9520379; http://dx.doi.org/10.1073/pnas.95.7.3408
9. S.Gerhardt, G.Hassall, P.Hawtin, E.McCall, L.Flavell, C.Minshull, D.Hargreaves, A.Ting, R.A.Pauptit, A.E.Parker, et al. Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains. J Mol Biol 2007; 373:891-902; PMID:17897672; http://dx.doi.org/10.1016/j.jmb.2007.07.047
10. L.Mosyak, K.Georgiadis, T.Shane, K.Svenson, T.Hebert, T.McDonagh, S.Mackie, S.Olland, L.Lin, X.Zhong, et al. Crystal structures of the two major aggrecan degrading enzymes, ADAMTS4 and ADAMTS5. Protein Sci 2008; 17:16-21; PMID:18042673; http://dx.doi.org/10.1110/ps.073287008
11. H.S.Shieh, K.J.Mathis, J.M.Williams, R.L.Hills, J.F.Wiese, T.E.Benson, J.R.Kiefer, M.H.Marino, J.N.Carroll, J.W.Leone, et al. High resolution crystal structure of the catalytic domain of ADAMTS-5 (aggrecanase-2). J Biol Chem 2008; 283:1501-7; PMID:17991750; http://dx.doi.org/10.1074/jbc.M705879200
12. N.G.Li, Z.H.Shi, Y.P.Tang, L.Wei, Y.Lian, J.A.Duan. Discovery of selective small molecular TACE inhibitors for the treatment of rheumatoid arthritis. Curr Med Chem 2012; 19:2924-56; PMID:22519396; http://dx.doi.org/10.2174/092986712800672120
13. R.Stawikowska, M.Cudic, M.Giulianotti, R.A.Houghten, G.B.Fields, D.Minond. Activity of ADAM17 (a disintegrin and metalloprotease 17) is regulated by its noncatalytic domains and secondary structure of its substrates. J Biol Chem 2013; 288:22871-9; PMID:23779109; http://dx.doi.org/10.1074/jbc.M113.462267
14. J.Rios-Doria, D.Sabol, J.Chesebrough, D.Stewart, L.Xu, R.Tammali, L.Cheng, Q.Du, K.Schifferli, R.Rothstein, et al. A monoclonal antibody to ADAM17 inhibits tumor growth by inhibiting EGFR and Non-EGFR-mediated pathways. Mol Cancer Ther 2015; 14:1637-49; PMID:25948294; http://dx.doi.org/10.1158/1535-7163.MCT-14-1040
15. A.C.Martin, J.M.Thornton. Structural families in loops of homologous proteins:automatic classification, modelling and application to antibodies. J Mol Biol 1996; 263:800-15; PMID:8947577; http://dx.doi.org/10.1006/jmbi.1996.0617
16. R.D.Mazzola, Jr., Z.Zhu, L.Sinning, B.McKittrick, B.Lavey, J.Spitler, J.Kozlowski, S.Neng-Yang, G.Zhou, Z.Guo, et al. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II:optimization of the S3′ pocket. Bioorg Med Chem Lett 2008; 18:5809-14; PMID:18835710; http://dx.doi.org/10.1016/j.bmcl.2008.09.045
17. S.DasGupta, P.R.Murumkar, R.Giridhar, M.R.Yadav. Studies on novel 2-imidazolidinones and tetrahydropyrimidin-2(1H)-ones as potential TACE inhibitors:design, synthesis, molecular modeling, and preliminary biological evaluation. Bioorg Med Chem 2009; 17:3604-17; PMID:19394232; http://dx.doi.org/10.1016/j.bmc.2009.04.003
18. M.Wisniewska, P.Goettig, K.Maskos, E.Belouski, D.Winters, R.Hecht, R.Black, W.Bode. Structural determinants of the ADAM inhibition by TIMP-3:crystal structure of the TACE-N-TIMP-3 complex. J Mol Biol 2008; 381:1307-19; PMID:18638486; http://dx.doi.org/10.1016/j.jmb.2008.06.088
19. W.Yu, L.Tong, S.H.Kim, M.K.Wong, L.Chen, D.Y.Yang, B.B.Shankar, B.J.Lavey, G.Zhou, A.Kosinski, et al. Biaryl substituted hydantoin compounds as TACE inhibitors. Bioorg Med Chem Lett 2010; 20:5286-9; PMID:20663669; http://dx.doi.org/10.1016/j.bmcl.2010.06.134
20. C.Dai, D.Li, J.Popovici-Muller, L.Zhao, V.M.Girijavallabhan, K.E.Rosner, B.J.Lavey, R.Rizvi, B.B.Shankar, M.K.Wong, et al. 2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors. Bioorg Med Chem Lett 2011; 21:3172-6; PMID:21458257; http://dx.doi.org/10.1016/j.bmcl.2011.01.002
21. C.J.Tape, S.H.Willems, S.L.Dombernowsky, P.L.Stanley, M.Fogarasi, W.Ouwehand, J.McCafferty, G.Murphy. Cross-domain inhibition of TACE ectodomain. Proc Natl Acad Sci U S A 2011; 108:5578-83; PMID:21415364; http://dx.doi.org/10.1073/pnas.1017067108
22. H.F.Kwok, K.A.Botkjaer, C.J.Tape, Y.Huang, J.McCafferty, G.Murphy. Development of a ‘mouse and human cross-reactive’ affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy. Protein Eng Des Sel 2014; 27:179-90; PMID:24769623; http://dx.doi.org/10.1093/protein/gzu010
23. P.W.Janes, N.Saha, W.A.Barton, M.V.Kolev, S.H.Wimmer-Kleikamp, E.Nievergall, C.P.Blobel, J.P.Himanen, M.Lackmann, D.B.Nikolov. Adam meets Eph:an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 2005; 123:291-304; PMID:16239146; http://dx.doi.org/10.1016/j.cell.2005.08.014
24. K.Althoff, P.Reddy, N.Voltz, S.Rose-John, J.Mullberg. Shedding of interleukin-6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. Eur J Biochem 2000; 267:2624-31; PMID:10785383; http://dx.doi.org/10.1046/j.1432-1327.2000.01278.x
25. C.L.Hinkle, S.W.Sunnarborg, D.Loiselle, C.E.Parker, M.Stevenson, W.E.Russell, D.C.Lee. Selective roles for tumor necrosis factor alpha-converting enzyme/ADAM17 in the shedding of the epidermal growth factor receptor ligand family:the juxtamembrane stalk determines cleavage efficiency. J Biol Chem 2004; 279:24179-88; PMID:15066986; http://dx.doi.org/10.1074/jbc.M312141200
26. R.Chen, L.Li, Z.Weng. ZDOCK:an initial-stage protein-docking algorithm. Proteins 2003; 52:80-7; PMID:12784371; http://dx.doi.org/10.1002/prot.10389
27. B.R.Brooks, R.E.Bruccoleri, B.D.Olafson, D.J.States, S.Swaminathan, M.Karplus. Charmm - a program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 1983; 4:187-217; http://dx.doi.org/10.1002/jcc.540040211
28. L.Li, R.Chen, Z.Weng. RDOCK:refinement of rigid-body protein docking predictions. Proteins 2003; 53:693-707; PMID:14579360; http://dx.doi.org/10.1002/prot.10460
29. C.Chothia, A.M.Lesk. Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 1987; 196:901-17; PMID:3681981; http://dx.doi.org/10.1016/0022-2836(87)90412-8
30. H.S.Shieh, A.G.Tomasselli, K.J.Mathis, M.E.Schnute, S.S.Woodard, N.Caspers, J.M.Williams, J.R.Kiefer, G.Munie, A.Wittwer, et al. Structure analysis reveals the flexibility of the ADAMTS-5 active site. Protein Sci 2011; 20:735-44; PMID:21370305; http://dx.doi.org/10.1002/pro.606
31. C.Camodeca, E.Nuti, L.Tepshi, S.Boero, T.Tuccinardi, E.A.Stura, A.Poggi, M.R.Zocchi, A.Rossello. Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models. Eur J Med Chem 2016; 111:193-201; PMID:26871660; http://dx.doi.org/10.1016/j.ejmech.2016.01.053
32. H.Liu, A.H.Shim, X.He. Structural characterization of the ectodomain of a disintegrin and metalloproteinase-22 (ADAM22), a neural adhesion receptor instead of metalloproteinase:insights on ADAM function. J Biol Chem 2009; 284:29077-86; PMID:19692335; http://dx.doi.org/10.1074/jbc.M109.014258